Skip to content
Screener

Gilead Sciences GILD AOCI - Foreign Currency Translation Adjustment, Net of Tax

AOCI - Foreign Currency Translation Adjustment, Net of Tax at other companies

Better Home & Finance logo
Better Home & FinanceBETR
-$1.63M-173%
SBA Communications logo
SBA CommunicationsSBAC
$16.26M-72.2%
Teledyne Technologies logo
Teledyne TechnologiesTDY
-$63.9M-142%
Veeva Systems logo
Veeva SystemsVEEV
-$766K-61.3%
Insmed logo
InsmedINSM
-$668K-137%
SolarEdge Technologies logo
SolarEdge TechnologiesSEDG
$14.73M

Other financials

Income statement

See full
Revenue$7.8B+10.2%
Gross profit$6.2B+11.5%
Operating income-$10.4B-520%
Net income-$10.5B-636%
EPS (diluted)-$8.45-642%

Balance sheet

See full
Cash & equivalents$3.2B-38.2%
Total debt$26.2B+5.2%
Total equity$11.8B-39.9%
Total assets$49.4B-11.4%

Cash flow

See full
Operating cash flow$3.6B+332%
CapEx$140.0M+30.8%
Free cash flow$3.4B+377%

Valuation

See full
Market cap$163.59B+19.3%
Enterprise value$186.66B+18.9%
P/S5.4×+0.6×

Profitability

See full
Gross margin79.6%+1.1pp
Operating margin-8.2%-36.1pp
Net margin-10.6%-32.5pp
FCF margin42.5%+10.0pp

Returns & leverage

See full
Return on equity-20.6%-53.8pp
Debt / equity2.2×+1.0×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept gild:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLossCumulativeGainLoss.

The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000882095-26-000031
(in millions)June 30, 2026 / Gross Carrying AmountJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Foreign Currency Translation AdjustmentJune 30, 2026 / Net Carrying AmountDecember 31, 2025 / Gross Carrying AmountDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Foreign Currency Translation AdjustmentDecember 31, 2025 / Net Carrying Amount
Intangible asset – sofosbuvir$10,720$(8,797)$1,923$10,720$(8,448)$2,272
Intangible asset – axicabtagene ciloleucel7,110(3,330)3,7807,110(3,127)3,983
Intangible asset – Trodelvy11,730(4,704)7,02611,730(4,164)7,566
Intangible asset – Hepcludex(1)1,395(462)933845(415)430
Other1,458(1,087)3721,483(1,056)428
Total finite-lived assets32,413(18,382)14,03231,888(17,211)14,678
Indefinite-lived assets – IPR&D(1)(2)2,3002,300
Total intangible assets$32,413$(18,382)$14,032$34,188$(17,211)$16,978

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Gilead Sciences's AOCI - foreign currency translation adjustment, net of tax?
Gilead Sciences (GILD) reported AOCI - foreign currency translation adjustment, net of tax of $0 in Q2 2026.
What is the long-term trend for Gilead Sciences's AOCI - foreign currency translation adjustment, net of tax?
Over 5 years (2020 to 2025), Gilead Sciences's AOCI - foreign currency translation adjustment, net of tax has grown at a -100.0% compound annual growth rate (CAGR), from -$1M to $0.
What does AOCI - foreign currency translation adjustment, net of tax mean?
Cumulative foreign currency translation adjustments included in AOCI, net of tax.

Ask your AI about Gilead Sciences's aoci - foreign currency translation adjustment, net of tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude